Lung cancer is one of the most frequently diagnosed cancers and is the leading cause of
cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous …

Lung cancer has a poor prognosis; over half of people diagnosed with lung cancer die
within one year of diagnosis and the 5-year survival is less than 18%. Non-small cell lung …

Lung cancer remains the leading cause of cancer deaths. Non-small cell lung cancer
(NSCLC) is the most frequent subtype of lung cancer. Surgery, radiation, chemotherapy …

Lung cancer, of which non-small lung cancer is the most common subtype, represents the
leading cause of cancer related-death worldwide. It is now recognized that a significant …

Lung cancer remains one of the greatest medical challenges with nearly 1.5 million new
cases worldwide each year and a growing tobacco epidemic in the developing world. This …

The understanding of genetic alterations that drive non-small cell lung cancer (NSCLC) is
evolving. As many of these molecularly-defined subtypes are potentially actionable, new …

Historically, patients with advanced stage non‐small cell lung cancer (NSCLC) were treated
with chemotherapy alone, but a therapeutic plateau has been reached. Advances in the …

Continuous revision of the histologic and stage-wise classification of lung cancer by the
World Health Organization (WHO) provides the foundation for therapeutic advances by …

The mortality of lung cancer is surprising, even though the development of different
treatments and diagnosis methods. Besides, non-small cell lung cancer (NSCLC) takes a …

The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been
evolving beyond chemotherapy over the last few years. The discovery of oncogenic driver …